The Inflation Reduction Act (IRA) is set to bring significant changes to the pharmaceutical industry. With the final negotiated maximum fair price (MFP) for the first 10 selected products announced on September 1, 2024, and set to take effect on January 1, 2026, the landscape is already shifting.

This engaging cross-disciplinary program examined the IRA’s potential impact on pharmaceutical patent dynamics and drug valuation and pricing, as well as pending legal challenges to the IRA.

Discussion topics included the IRA’s impact on:

• Existing incentives to encourage investment in post-approval research and development
• Strategic investment decisions in pharmaceutical products
• The biosimilar and generic markets, including market entry strategies
• Drug pricing dynamics, including proposed methodologies for identifying and reconciling purchases for drugs subject to the MFP and eligible for 340B pricing
• The pending legal challenges to the IRA and their future impact on the program